Search
Selected Filters
Displaying 21–30 of 257 research results
-
Eye On the Cure Research News
Most participants with advanced retinitis pigmentosa (RP) in the trial had improved navigation and/or object discrimination in reduced lighting conditions
-
Eye On the Cure Research News
Geographic atrophy (GA) is the advanced form of dry age-related macular degeneration (AMD) which causes blindness in one million people in the United States and 5 million worldwide.
This is the first time that a treatment has been approved for this leading cause of blindness.
-
Opus Genetics Acquires Rights to Gene Therapies for BEST1 and RP (RHO)
Eye On the Cure Research NewsThe company plans to seek clinical trial authorization for the BEST1 gene therapy during the second half of 2023
-
SparingVision Receives Authorization to Launch US Clinical Trial for its Cone-Preserving Treatment
Eye On the Cure Research NewsThe emerging therapy is designed to work independent of the mutated gene causing retinitis pigmentosa
-
Opus Genetics to Launch Gene Therapy Clinical Trial for LCA5 Patients
Eye On the Cure Research NewsThe LCA5 gene therapy will be the first emerging Opus treatment to move into a human study
-
Editas Reports Results for 14 Participants in its Phase 1/2 CRISPR/Cas9 Clinical Trial for LCA10
Eye On the Cure Research NewsThe company is seeking a partner to move the LCA10 program forward
-
Recap of Retinal Disease News from the 2022 Meeting of the American Academy of Ophthalmology
Eye On the Cure Research NewsReports on emerging therapies for dry age-related macular degeneration (geographic atrophy), Stargardt disease, and X-linked retinitis pigmentosa are included
-
Atsena’s LCA-GUCY2D Gene Therapy Improves Vision in Phase 1/2 Clinical Trial
Eye On the Cure Research NewsThe company is planning to move the emerging treatment into a pivotal trial
-
Eye On the Cure Research News
Small data sets present challenges for developing rare disease AI tools
-
Iveric Bio’s Zimura for Advanced Dry AMD Meets Endpoint in Second Phase 3 Clinical Trial
Eye On the Cure Research NewsThe company plans to seek FDA approval for the emerging therapy in first quarter of 2023
.png)
.png)
